Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1354949 | 0.84 | ALOX12 (0.58) | CYP19A1MEN1TP53KMT2ATSHR | |
| SCHEMBL6915427 | 0.81 | FEN1 (0.47) | CYP19A1HTR2AMEN1KMT2APKM | |
| SCHEMBL30897273 | 0.80 | ALDH1A1 (0.54) | MEN1TP53KMT2ARXFP1PKM | |
| SCHEMBL15416652 | 0.80 | ALDH1A1 (0.54) | MEN1TP53KMT2ARXFP1PKM | |
| SCHEMBL9426286 | 0.79 | NSD2 (0.47) | CYP19A1MEN1KMT2APKMALDH1A1 | |
| SCHEMBL20163593 | 0.78 | CYP19A1 (0.50) | CYP19A1ALDH1A1NR3C1MGAM | |
| SCHEMBL19559085 | 0.78 | GPR84 (0.49) | HTR2AMEN1TP53KMT2ARXFP1 | |
| SCHEMBL6923053 | 0.76 | PBRM1 (0.50) | MEN1KMT2APKMALDH1A1TSHR | |
| SCHEMBL29557960 | 0.75 | PBRM1 (0.52) | MEN1TP53KMT2ARXFP1PKM | |
| SCHEMBL15415994 | 0.75 | PBRM1 (0.52) | MEN1TP53KMT2ARXFP1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122076-A1 | Sulphonamides for the treatment of central nervous system diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
| EP-1335720-A1 | SULPHONAMIDES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | Bayer Aktiengesellschaft (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-6498183-B1 | TREATMENT AND PROPHYLAXIS OF DISORDERS CAUSED BY HERPES VIRUSES, IN PARTICULAR HUMAN CYTOMEGALOVIRUS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-24 | — | — | US | disclosed |
| WO-2002036115-A1 | SULPHONAMIDES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-10 | — | — | WO | disclosed |
| EP-1177171-A1 | SUBSTITUTED INDOLE SULFONAMIDES AS ANTIVIRAL AGENTS | Bayer Aktiengesellschaft (DE) | 2002-02-06 | — | — | EP | disclosed |
| WO-2000066553-A1 | SUBSTITUTED INDOLE SULFONAMIDES AS ANTIVIRAL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122076-A1 | Sulphonamides for the treatment of central nervous system diseases | HTR6, SLC6A4, AANAT | CYP19A1 3120/4885HTR2A 12/4885MEN1 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.